Up-Regulation of MiR-330-5p is Associated with the Advanced Clinical Stage of Hepatocellular Carcinoma

Abstract

\n Purpose: A opposite expression levels and roles of miR-330-5p in hepatocellular carcinoma (HCC) have been reported in previous studies, so the clinicopathological implications and the prospective molecular mechanism of miR-330-5p in HCC require elaboration.Materials and methods: To examine the mRNA expression profile of hsa-miR-330-5p in HCC, a in-house RT-qPCR was performed, and the expression data was extracted from sequencing data and gene microarrays from the datasets of The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), ONCOMINE, ArrayExpress, and Sequence Read Archive (SRA). To have an overview of the clinical value of miR-330-5p, all possible data were integrated to calculate the standard mean difference (SMD) and area under the curve (AUC) from summary receiver operating characteristic curve (sROC). The target genes of miR-330-5p were also predicted and the relative signaling pathways were investigated by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses.Results: According to the integrative analysis, the expression value of miR-330-5p in HCC was higher than in non-tumor tissue (SMD=0.47, 95CI%=0.31-0.63), and high expression of miR-330-5p was related with advanced HCC stage (SMD=0.27, 95CI%=0.08-0.46), poor differentiation (SMD=0.39, 95CI%=0.21-0.58) and poor prognosis (HR=1.91, Log-rank P=0.014). GLUD1, GOT1 and GLS2 were highly likely to be targeted by miR-330-5p, and the progression and prognosis of HCC might be influenced via the miR-330-5p–GLUD1/GOT1/GLS2 axis.Conclusion: The result showed a high-expressed level of miR-330-5p was in the HCC tissue compared with non-tumor tissue, and the overexpression of miR-330-5p indicated poor progression and prognosis in HCC.